First Author (Year) | Enrollment period | Country | Group | No. of patients | Gender (Male%) | Age | Primary tumor (Colon/ Rectum) | Number of metastases | Largest metastasis size(cm) | Synchronous liver metastases (%) | CEA level (ng/mL) | Type of survival outcomes | Follow-up (months) | NOS |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Andreou 2021 [9] | 2012–2019 | Switzerland | AR | 13 | 9(69.2%) | 61(30–79) | 9/4 | N/A | N/A | 9(100%) | N/A | OS, RFS | 55 | 8 |
PSR | 79 | 51(64.6%) | 62(36–84) | 59/20 | N/A | N/A | 45(57%) | N/A | ||||||
Dam 2014 [25] | 1991–2010 | The Netherlands | AR | 129 | 67(51.9%) | 64(24–82) | 79/50 | 4(1–12) | 3.0(0.0–20.0) | N/A | N/A | OS, DFS | 33(0–235) | 8 |
PSR | 169 | 110(65.1%) | 64(28–88) | 98/71 | 1(1–3) | 3.0(0.4–13.0) | N/A | N/A | ||||||
DeMatteo 2000 [17] | 2001–2013 | Italy | AR | 148 | 88(59%) | < 70:110(74%); > 70:38(26%) | 110/38 | > 1:30(20%) | ≥ 5 cm:48(32%) | N/A | < 200:101(92%); ≥ 200:9(8%) | OS | 25(1–140) | 7 |
PSR | 119 | 67(56%) | < 70:83(70%); > 70:36(30%) | 96/33 | > 1:23(19%) | ≥ 5 cm:19(16%) | N/A | < 200:84(90%); ≥ 200:9(10%) | ||||||
Donadon 2018 [31] | 2001–2013 | Italy | AR | 110 | 67(60%) | 63.8 ± 10.2 | N/A | 3.5 ± 2.6 | 4.9 ± 2.5 | 44(40%) | N/A | OS, DFS | 33(1–83) | 8 |
PSR | 110 | 74(67%) | 61.9 ± 11.0 | N/A | 3.7 ± 3.3 | 4.5 ± 2.5 | 43(39%) | N/A | ||||||
Finch 2007 [21] | 1993–2003 | UK | AR | 280 | 171(61%) | 63(26–84) | N/A | 2(1–14) | 4.5(0.7–20) | 117(41.8%) | 18 ng/dl(1–37,140) | OS, DFS | 33(24–144) | 7 |
PSR | 96 | 64(67%) | 63(24–79) | N/A | 1(1–9) | 3.3(0.4–15) | 36(38%) | 5 ng/dl(1–12,124) | ||||||
Guzzetti 2008 [22] | 1996–2005 | Italy | AR | 102 | 58(56.8%) | < 70:78(76.4%); > 70: 24(23.6%) | 55/21 | Single 59(61.4%); Multiple 37(38.6%) | > 5 cm:31(32.3) | N/A | < 200:52(89.6); ≥ 200:6(10.4) | OS, DFS | N/A | 8 |
PSR | 106 | 63(59.5%) | < 70: 77(72.6%); > 70: 29(27.4%) | 60/31 | Single 67(64.4%); Multiple 37(35.6%) | > 5 cm:21(20.8) | N/A | < 200:51(86.4); ≥ 200:8(13.6) | ||||||
Hosokawa 2017 [29] | 2000–2015 | France | AR | 242 | 141(58%) | 64.0 ± 10.0 | 158/84 | N/A | 2.04 ± 0.8 | 121(50%) | 159.7 ± 1,347.6 | OS, RFS | 41 | 8 |
PSR | 1478 | 888(60%) | 64.1 ± 11.0 | 980/498 | N/A | 1.93 ± 0.76 | 721(49%) | 65.7 ± 303.0 | ||||||
Joechle 2020 [34] | 2006–2016 | USA | AR | 105 | 69(65.7%) | 54(29–82) | 72/33 | 1(1–9) | 2.0(0.16–5.3) | 75(71%) | N/A | OS, RFS, liver-RFS | 43.1 | 7 |
PSR | 105 | 71(67.6%) | 56(26–79) | 82/23 | 1(1–8) | 1.8(0.1–5.8) | 81(77%) | N/A | ||||||
Kokudo 2001 [18] | 1980–1999 | Japan | AR | 96 | 54(56.3%) | 58.7 ± 1.0 | 71/25 | Single:54(56.3%); ≥ 3:20(20.8%) | 5.81 ± 0.4 | 46(47.9%) | N/A | OS | N/A | 7 |
PSR | 78 | 46(59%) | 60.3 ± 1.2 | 49/29 | Single:42(53.8%); ≥ 3:19(24.4%) | 2.69 ± 0.16 | 56(71.8%) | N/A | ||||||
Lalmahomed 2011 [24] | 2000–2008 | Netherlands | AR | 88 | 56(64%) | 65(30–82) | 55/33 | 2(1–7) | 4(1–15) | 35(40%) | > 200:10(12%) | OS, DFS | 35(1–111) | 8 |
PSR | 113 | 70(62%) | 65(36–86) | 59/54 | 1(1–7) | 3(1–7) | 43(38%) | > 200:6(5%) | ||||||
Lordan 2017 [30] | 2000–2010 | UK | AR | 238 | 130(54.6%) | 64.8(24–86) | N/A | Single:161(67.7%); Mutiple:76(31.9%) | 3.2(0.4–20) | 14 (5.9) | N/A | OS, DFS | 36(0.12–144) | 8 |
PSR | 238 | 135(56.7%) | 65.7(31–87) | N/A | Single:153(64.3%); Mutiple:85(35.7%) | 3.1(0.5–14) | 15 (6.3) | N/A | ||||||
Matsuki 2016 [26] | 2005–2013 | Japan | AR | 23 | 17(74%) | 62(29–84) | 15/8 | 5(1–17) | 2.0(0.5–3) | 13(57) | 4.9(0.6–230) | OS, RFS, Liver-RFS | 40(5–81) | 8 |
PSR | 40 | 25(63%) | 64(40–81) | 26/14 | 4(1–27) | 1.8(0.5–3) | 18(45) | 4.2(0.5–117) | ||||||
Matsumura 2016 [27] | 1999–2012 | Japan | AR | 32 | 22(68.8) | 62.5(27–80) | 22/10 | 7(4–31) | 3.0(0.8–5) | N/A | 9.35(0.6–975) | OS, RFS, Liver-RFS | N/A | 7 |
PSR | 113 | 74(65.5) | 60(40–81) | 65/48 | 6(4–33) | 2.5(0.4–5) | N/A | 7(0.5–3097) | ||||||
Memeo 2016 [28] | 2006–2013 | France | AR | 266 | 145(55%) | 61(29–82) | 189/77 | 4(3–15) | 3.3(0.6–20) | 127(48%) | N/A | OS, DFS | N/A | 8 |
PSR | 266 | 146(55%) | 62.4(40–80) | 194/72 | 4(3–9) | 3.5(0.6–11) | 134(50%) | N/A | ||||||
Mise 2016 [8] | 1993–2013 | Houston | AR | 144 | 80(56%) | 58(22–87) | 105/39 | N/A | 1.9(0.3–3.0) | 17(12%) | 2.9(0.4–250.3) | OS, RFS, Liver-RFS | 37(2—208) | 8 |
PSR | 156 | 94(61%) | 60(30–88) | 113/43 | N/A | 1.5(0.4–3.0) | 50(32%) | 2.5(0.4–430.9) | ||||||
Okumura 2019 [10] | 2004–2017 | France | AR | 82 | 51(62.2%) | 64(43–85) | 55/27 | 2(1–8) | 2.8(0.5–13) | 50(61%) | N/A | OS, RFS, Liver-RFS | 33.9(6–120) | 8 |
PSR | 82 | 50(61%) | 65(33–83) | 48/34 | 2(1–7) | 2.5(0.5–15) | 45(54.9%) | N/A | ||||||
Pandanaboyana 2018 [32] | 1993–2011 | UK | AR | 582 | N/A | < 65:282(48.5%); > 65:300(51.5%) | N/A | 2 | 4.5(3–7) | 294(50.5%) | N/A | OS, DFS | 32.2(17.5–56.9) | 8 |
PSR | 409 | N/A | < 65:175(42.8%); > 65:234(57.2%) | N/A | 2 | 2.7(2–4) | 228(55.7%) | N/A | ||||||
Sarpel 2009 [23] | 1987–2007 | USA | AR | 94 | 54(57%) | 60.8 ± 10.4 | 60/10 | 1.7 ± 1.2 | 6.6 ± 4.7 | 8(8%) | N/A | OS, DFS | 34 | 8 |
PSR | 89 | 51(57%) | 62.3 ± 11.6 | 59/12 | 1.4 ± 1.0 | 3.5 ± 2.3 | 8(9%) | N/A | ||||||
She 2020 [35] | 1990–2017 | China | AR | 70 | 38(54.3%) | 61.0(29–85) | N/A | 1(1–7) | 2.45(1.0–11.0) | 38(55.1%) | 8.8(0.7–802) | OS, DFS | 39.8(2.9–183.9) | 8 |
PSR | 70 | 47(67.1%) | 61.0(31–85) | N/A | 1(1–multiple) | 2.5(0.9–11.0) | 27(38.6%) | 8.85(1–526) | ||||||
Spelt 2018 [33] | 2006–2014 | Sweden | AR | 60 | 39(65%) | 65(61–69) | N/A | 3(2–5) | 2.65(1.7–4.0) | 38(64.4%) | 5(3–18) | OS | 35 | 7 |
PSR | 59 | 35(59.3%) | 69(63–76) | N/A | 2(2–4) | 2.2(1.5–3.0) | 29(51.8%) | 5(3–17) | ||||||
Stewart 2004 [19] | 1988–2001 | UK | AR | 69 | N/A | 62(23–79) | N/A | 1–3:65(97%); > 3:2/67(3%) | < 5 cm:14(23.3%); > 5 cm:46(76.7%) | N/A | 625U/l(14–308,040) | OS | N/A | 7 |
PSR | 27 | N/A | 64(28–82) | N/A | 1–3:22(91.7%); > 3:2(8.3%) | < 5 cm:14(77.7%); > 5 cm:4(22.3%) | N/A | 105U/l(1–2662) | ||||||
Zorzi 2006 [20] | 1991–2004 | Italy | AR | 181 | 113(62.4%) | < 65:120(66.3%); > 65:61(33.7%) | 113/46 | Single:99(54.7%); Multiple:82(45.3%) | 3(0.3–18) | 73(40.3%) | < 200:160(88.4%); > 200:7(3.9%) | OS | 25 | 7 |
PSR | 72 | 46(64%) | < 65:44(61%); > 65:28(39%) | 42/17 | Single:45(62.5%); Multiple:27(37.5%) | 2.1(0.5–6) | 25(34.7%) | < 200:63(87.5%); > 200:1(1.4%) |